Immune Design Corp., a clinical-stage immunotherapy company, focuses on cancer with in vivo approaches to enable the body’s immune system to fight disease. The company develops products based on its ZVex and GLAAS discovery platforms. Its lead product candidate is G100, a monotherapy and combination therapy that is in Phase II clinical trials for treating patients with follicular non-Hodgkin lymphoma. The company has collaboration and license agreements with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck Sharp & Dohme Corp. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck & Co., Inc.